Name

Isotype

Target

NCT Number

Study Design

Clinical Trial Phase

Nivolumab

IgG4

PD-1

02576509

RCT

III

Pembrolizumab

IgG4

PD1

02702401

RCT

III

Tremelimumab

IgG2

CTLA-4

02519348

RCT

II

Durvalumab

IgG1

PD-L1